Ieq Capital LLC Acquires 85,004 Shares of Sana Biotechnology, Inc. $SANA

Ieq Capital LLC raised its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 428.7% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 104,832 shares of the company's stock after purchasing an additional 85,004 shares during the quarter. Ieq Capital LLC's holdings in Sana Biotechnology were worth $176,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Sana Biotechnology by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company's stock worth $457,000 after purchasing an additional 6,613 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Sana Biotechnology by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company's stock worth $578,000 after purchasing an additional 7,230 shares during the period. Hsbc Holdings PLC lifted its position in Sana Biotechnology by 26.5% during the first quarter. Hsbc Holdings PLC now owns 41,377 shares of the company's stock valued at $65,000 after purchasing an additional 8,673 shares in the last quarter. Rhumbline Advisers lifted its position in Sana Biotechnology by 5.4% during the first quarter. Rhumbline Advisers now owns 182,134 shares of the company's stock valued at $306,000 after purchasing an additional 9,359 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in Sana Biotechnology by 25.4% during the fourth quarter. ProShare Advisors LLC now owns 47,808 shares of the company's stock valued at $78,000 after purchasing an additional 9,679 shares in the last quarter. Institutional investors own 88.23% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SANA. JMP Securities reissued a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley began coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 price target for the company. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $8.00.

Sana Biotechnology Stock Performance

Shares of SANA traded up $0.02 during mid-day trading on Tuesday, hitting $3.02. 2,075,076 shares of the stock were exchanged, compared to its average volume of 4,375,889. The company has a market cap of $718.19 million, a PE ratio of -2.85 and a beta of 1.88. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $7.30. The firm has a 50-day moving average of $3.72 and a two-hundred day moving average of $2.70.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. On average, sell-side analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.